Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 31, 2015 06:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics to Acquire Rare Disease Company Scioderm, Inc.

Scioderm's Lead Drug Candidate Zorblisa™ in Phase 3 Study for Rare Disease Epidermolysis Bullosa (EB) Granted FDA Breakthrough Therapy Designation FDA Has Agreed to Rolling NDA Submission...
August 05, 2015 16:01 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Announces Second Quarter 2015 Financial Results and Corporate Updates

Marketing Submissions for Galafold® (migalastat HCl) for Fabry Disease Under Review in Europe and on Track for Filing in 2H15 in United States 2Q15 Equity Financing Significantly Strengthens...
July 29, 2015 07:30 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics to Announce Second Quarter 2015 Financial Results on August 5, 2015

CRANBURY, N.J., July 29, 2015 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced a conference call and live audio webcast on Wednesday, August 5, 2015 at 5:00 p.m. ET to discuss...
June 29, 2015 07:30 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Joins Russell 3000(R) and Russell 2000(R) Indexes

CRANBURY, N.J., June 29, 2015 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, has been added to the U.S....
June 25, 2015 16:01 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Announces Galafold(TM) Marketing Authorization Application (MAA) Validated by European Medicines Agency (EMA)

CRANBURY, N.J., June 25, 2015 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced that the...
June 17, 2015 16:01 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Announces Closing of Underwritten Offering of Common Stock and Full Exercise of Over-Allotment Option

CRANBURY, N.J., June 17, 2015 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced the closing...
June 11, 2015 20:10 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Prices Underwritten Offering of Common Stock

CRANBURY, N.J., June 11, 2015 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced the pricing...
June 10, 2015 16:01 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Announces Public Offering of Common Stock

CRANBURY, N.J., June 10, 2015 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced it has...
June 08, 2015 07:30 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Strengthens Executive Leadership Team

Adds Two Former Heads of Global Marketing From Leading Rare Disease Companies in Fabry Field Hung Do, Ph.D. Promoted to Chief Science Officer CRANBURY, N.J., June 8, 2015 (GLOBE NEWSWIRE) --...
June 03, 2015 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Submits Marketing Authorization Application (MAA) for Full Approval of Fabry Monotherapy Galafold(TM) (Migalastat) in European Union

MAA Submission Under "Accelerated Assessment" Brand Name Galafold™ Approved by Regulatory Authorities in EU and U.S. CRANBURY, N.J., June 3, 2015 (GLOBE NEWSWIRE) -- Amicus Therapeutics...